Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25991088 | 0.79 | ALDH1A1 (0.50) | CYP1A2CYP2C9CYP2C19ALDH1A1ADRA2A | |
| SCHEMBL6006538 | 0.79 | ALDH1A1 (0.54) | CYP1A2CYP2C9CYP2C19ALDH1A1ADRA2A | |
| SCHEMBL20307886 | 0.76 | ALDH1A1 (0.47) | CYP1A2CYP2C9CYP2C19ALDH1A1ADRA2A | |
| SCHEMBL615615 | 0.76 | CYP1A2 (0.50) | CYP1A2CYP2C9CYP2C19ALDH1A1ADRA2A | |
| SCHEMBL30692103 | 0.76 | CYP1A2 (0.50) | CYP1A2CYP2C9CYP2C19ALDH1A1ADRA2A | |
| SCHEMBL714591 | 0.75 | ALDH1A1 (0.46) | CYP1A2CYP2C9CYP2C19ALDH1A1ADRA2A | |
| SCHEMBL29648886 | 0.75 | ALDH1A1 (0.46) | CYP1A2CYP2C9CYP2C19ALDH1A1ADRA2A | |
| SCHEMBL29450632 | 0.75 | ALDH1A1 (0.46) | CYP1A2CYP2C9CYP2C19ALDH1A1ADRA2A | |
| SCHEMBL29450615 | 0.75 | ALDH1A1 (0.46) | CYP1A2CYP2C9CYP2C19ALDH1A1ADRA2A | |
| SCHEMBL547207 | 0.75 | ALDH1A1 (0.46) | CYP1A2CYP2C9CYP2C19ALDH1A1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241770-B2 | Hydronopol derivatives as agonists on human ORL1 receptors | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-20050131004-A1 | Hydronopol derivatives as agonists on human ORL1 receptors | SOLVAY PHARMACEUTICALS GMBH. | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131004-A1 | Hydronopol derivatives as agonists on human ORL1 receptors | OPRL1, ORMDL3, OGFRL1 | CYP1A2 946/4885CYP2C9 2709/4885CYP2C19 2217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.